According to the researchers’ findings, the cross-reaction between EPHB4 and platelet-derived growth factor receptor-β (PDGFRβ), which also constitutes a tyrosine kinase receptor, contributes to the excessively poor prognosis in ARMS patients [29]. The gene discussed is EPHB4; the disease is alveolar rhabdomyosarcoma.